Introducing Agonist Redirected Checkpoint (ARC) Therapeutics for Cancer Immunotherapy and Inflammation.

OUR VISION

Shattuck Labs is developing a breakthrough platform for immunotherapy, which harnesses the human immune system to improve survival for patients battling cancer and inflammatory disease. Shattuck has developed immunotherapy agents for patients with many cancer types, including melanoma, lung, and bladder. Shattuck’s proprietary technology represents the next evolutionary step in cancer therapy by endowing one molecule with multiple functions, building directly on the clinical success of Opdivo, Keytruda and Tecentriq, with applicability across the entire spectrum of human disease.

OUR COMPANY

Shattuck Labs, based in Austin, Texas, is a privately-held biotechnology company founded in 2016 by Josiah Hornblower (CEO, Chairman, and Co-founder) and Taylor Schreiber, MD, PhD (Chief Scientific Officer, Co-founder).

OUR TEAM

Shattuck has attracted a world-class group of executives, directors and scientific advisors to lead development of the ARC platform and guide corporate strategy.

BOARD OF DIRECTORS

Josiah Homblower
CEO, Chairman, and Co-founder

Taylor H. Schreiber, MD, PhD
Chief Scientific Officer, Co-founder

Neil Gibson, PhD
Chief Scientific Officer, Biologics, COI Pharma

David G. Lowe, PhD
Investor and Entrepreneur

G. Walter Loewenbaum
Chairman of the Board & Executive Committee, Luminex

Tyler Brous
Portfolio Manager, Lennox Capital Partners, LP

SENIOR MANAGEMENT

Lini Pandite, MD
Chief Medical Officer

Andrew R. Neill
Vice President of Corporate Development & Strategy

Kate V. Seaber, BSc, MBA, PMP
Vice President of Development

George Fromm, PhD
Vice President of Research & Development

SCIENTIFIC ADVISORY BOARD

Keith T. Flaherty, MD
Dana-Farber / Harvard Cancer Center

Charles G. Drake, MD, PhD
Columbia University Medical Center

Johann De Bono, MD, PhD
The Institute of Cancer Research

Dmitry Gabrilovich, MD, PhD
The Wistar Institute

Matthew Hellmann, MD
Memorial Sloan Kettering Cancer Center

OUR PARTNERS

Shattuck has attracted an outstanding base of early investors and partners as a result of its immunology and development expertise and the transformative potential of the ARC platform.